フルテキストファイル
著者
小山 哲史 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧
三宅 成智 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
藤原 和典 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
Morisaki, Tsuyoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine
福原 隆宏 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
Kitano Hiroya Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine / Center for Head and Neck Surgery, Kusatsu General Hospital
竹内 裕美 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
キーワード
Lenvatinib
Anaplastic thyroid cancer
Chemotherapy
Hypothyroidism
Tyrosine kinase inhibitor
抄録
Background: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism; the incidence of hypothyroidism with lenvatinib is unclear. Objectives: We conducted a retrospective study to investigate the efficacy and safety of lenvatinib in ATC. Methods: Five patients with unresectable ATC were enrolled. Lenvatinib 24 mg once daily was administered until disease progression, unmanageable toxicity, withdrawal, or death occurred. We retrospectively analyzed objective response rate (ORR), time to progression (TTP), overall survival, and safety. Results: Three of the five patients (60%) had a partial response, and two (40%) had stable disease. ORR was 60%. Median TTP was 88 days, and overall survival was 165 days. Hypothyroidism was a common treatment-related adverse effect; four patients (80%) had hypothyroidism of any grade. These four patients had not undergone total thyroidectomy prior to lenvatinib administration, and the other patient had undergone total thyroidectomy. Treatment-related adverse effects of any grade were hypertension in 80% of patients, diarrhea in 40%, fatigue in 80%, and decreased appetite in 80%. Conclusions: Lenvatinib is an effective treatment and may improve the prognosis of unresectable ATC. Four of five patients had hypothyroidism, which may have been associated with treatment-induced injury of the thyroid gland. There were many treatment-related adverse effects, most of which were manageable by dose modification and medical therapy.
出版者
S. Karger AG
資料タイプ
学術雑誌論文
外部リンク
ISSN
22350640
EISSN
22350802
掲載誌名
EUROPEAN THYROID JOURNAL
最新掲載誌名
EUROPEAN THYROID JOURNAL
7
3
開始ページ
139
終了ページ
144
発行日
2018-06
出版者DOI
著者版フラグ
著者版
著作権表記
© 2018 European Thyroid Association Published by S. Karger AG, Basel. This is the peer-reviewed but unedited manuscript version of the following article: Eur Thyroid J 2018;7:139-144. (doi: 10.1159/000485972). The final, published version is available at http://www.karger.com/?doi=10.1159/000485972
掲載情報
Koyama Satoshi, Miyake Naritomo, Fujiwara Kazunori, et al. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction. EUROPEAN THYROID JOURNAL. 2018. 7(3). 139-144. doi:10.1159/000485972
部局名
医学部・医学系研究科・医学部附属病院
言語
英語
Web of Science Key ut
WOS:000438872900005